Navigation Links
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
Date:8/5/2009

al Flu vaccine."

"The accomplishments announced today further validate our strategy to create a rapid, in-border influenza vaccine solution for governments around the world by addressing gaps in currently available vaccine technologies," added Dr. Rahul Singhvi, President and CEO of Novavax, Inc.

Novavax, Inc has successfully completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The Company plans to initiate a Phase II study with its Seasonal Flu vaccine candidate in the elderly population during Q4, 2009.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
2. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
5. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
6. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
7. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
8. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
9. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
10. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
11. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Chief Executive Officer, will be presenting at the 26 th ... Palace Hotel in New York . The ... 2:00 PM ET. In addition, Mr. Krakauer and Jorgen ... separate one-on-one meetings during the day. An ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... be Presented, PRINCETON, N.J., Sept. 4 ... nine clinical abstracts for ipilimumab,an investigational anti-CTLA-4 antibody, ... presentations at the 33rd Congress of the European ... 2008 in Stockholm.,Many of the following abstracts will ...
... for Targeted Therapies ... Benefits of Personalized Treatment HUNTINGTON BEACH, ... leader in molecular cancer diagnostics,today announced the launch of ... determine the gene expression levels of,the estrogen receptor (ER), ...
Cached Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication is ... states that, “While they give off the appearance of simplicity ... creating this powerful look.” , One of the first and ... kind of block matches your home environment and best fulfills ... main options are concrete and stone blocks. But do not ...
(Date:11/22/2014)... St. Petersburg, FL (PRWEB) November 22, 2014 ... Kitchen Innovations are pleased to announce that ... of the Thanksgiving #PayItForward contest. , Ms. Lombardo ... package from Kitchen Innovations. She wrote of how her ... beautiful, young daughters as a single mom. Despite medical ...
(Date:11/22/2014)... November 22, 2014 “Greenfield Naturals” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... the flavor of your water. , From pollution to ... important that everything is done to remove these chemicals, ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... Jerrold ... Connolly Medical Ltd. , ... (Vocus) January 29, 2010 -- Berkeley Heights – Jerrold S. Lozner, M.D., M.H.A., ... named as a “Top Doctor for Women’s Health” by Castle Connolly Medical, Ltd, in ...
... Pa. , Jan. 29 The Susan P. ... educate and inspire people of all ages to make healthy ... as President and CEO.  A talented non-profit leader, his goal ... expanding the delivery and distribution of health education services by ...
... , , Provides oral regime for hormone ... SPRING, Md. , Jan. 29 The U.S. ... with Femara (letrozole) to treat hormone positive and HER2-positive advanced ... indicated. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , HER2 ...
... respiratory weakness as a factor in the morbidity of ... that could improve long-term patient outcomes while reducing costs ... chair of research for the Department of Internal Medicine ... awarded a highly competitive, two-year, $480,000/year NIH Challenge Grant ...
... ... Following is the National Council on Disability,s monthly bulletin for December ... NCD,s award-winning Web site ( http://www.ncd.gov ), brings you the latest issues ... go to http://listserv.access.gpo.gov , click on "Online mailing list archives," select ...
... HANOVER TOWNSHIP, Pa. , Jan. 29 During a ... Secretary Everette James and Secretary of Education Gerald ... activity among middle school students. , "One-third of all Pennsylvania ... a lifetime of health problems," said James. "Schools like Hanover ...
Cached Medicine News:Health News:Summit Medical Group Physician Named 'Top Doctor for Women's Health' 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 2Health News:Susan P. Byrnes Health Education Center Names C.T. O'Donnell President and CEO 3Health News:FDA Expands Use of Approved Breast Cancer Drug 2Health News:FDA Expands Use of Approved Breast Cancer Drug 3Health News:Kentucky research looks at respiratory weakness in ICU morbidity 2Health News:National Council on Disability Monthly Bulletin for January 2010 2Health News:National Council on Disability Monthly Bulletin for January 2010 3Health News:National Council on Disability Monthly Bulletin for January 2010 4Health News:National Council on Disability Monthly Bulletin for January 2010 5Health News:National Council on Disability Monthly Bulletin for January 2010 6Health News:National Council on Disability Monthly Bulletin for January 2010 7Health News:National Council on Disability Monthly Bulletin for January 2010 8Health News:National Council on Disability Monthly Bulletin for January 2010 9Health News:State Health, Education Leaders Applaud Luzerne County School for Boosting Physical Activity Among Students 2
... your camera upon arrival.,Our technician then makes note ... with a thorough customer quote. We respect that ... so well help you prioritize repairs. With customer ... , ISI uses only OEM or widely approved ...
... carefully inspects your equipment upon arrival. Our technician ... and provides you with a thorough customer quote. ... a tight budget so well help you prioritize ... repair begins., , ISI uses only OEM or ...
... Infinity™ AST single liquid stable reagent ... quantitative determination of AST in serum. ... only provides excellent stability and convenience ... against existing assays. The reagent is ...
... Konelab 30 is a fully automated, versatile ... analytical needs in mind. Konelab 30 is ... tests, specific proteins, therapeutic drugs, drugs of ... applications. Its flexibility also makes the analyzer ...
Medicine Products: